These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Effect of warfarin on survival in scleroderma-associated pulmonary arterial hypertension (SSc-PAH) and idiopathic PAH. Belief elicitation for Bayesian priors. Johnson SR; Granton JT; Tomlinson GA; Grosbein HA; Hawker GA; Feldman BM J Rheumatol; 2011 Mar; 38(3):462-9. PubMed ID: 21159827 [TBL] [Abstract][Full Text] [Related]
10. Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Johnson SR; Mehta S; Granton JT Eur Respir J; 2006 Nov; 28(5):999-1004. PubMed ID: 17074918 [TBL] [Abstract][Full Text] [Related]
11. Anticoagulation in Pulmonary Arterial Hypertension. Robinson JC; Pugliese SC; Fox DL; Badesch DB Curr Hypertens Rep; 2016 Jun; 18(6):47. PubMed ID: 27137522 [TBL] [Abstract][Full Text] [Related]
12. Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). Preston IR; Roberts KE; Miller DP; Sen GP; Selej M; Benton WW; Hill NS; Farber HW Circulation; 2015 Dec; 132(25):2403-11. PubMed ID: 26510696 [TBL] [Abstract][Full Text] [Related]
13. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Olsson KM; Delcroix M; Ghofrani HA; Tiede H; Huscher D; Speich R; Grünig E; Staehler G; Rosenkranz S; Halank M; Held M; Lange TJ; Behr J; Klose H; Claussen M; Ewert R; Opitz CF; Vizza CD; Scelsi L; Vonk-Noordegraaf A; Kaemmerer H; Gibbs JS; Coghlan G; Pepke-Zaba J; Schulz U; Gorenflo M; Pittrow D; Hoeper MM Circulation; 2014 Jan; 129(1):57-65. PubMed ID: 24081973 [TBL] [Abstract][Full Text] [Related]
14. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. Johnson SR; Granton JT; Mehta S Chest; 2006 Aug; 130(2):545-52. PubMed ID: 16899857 [TBL] [Abstract][Full Text] [Related]
15. Anticoagulation in patients with pulmonary arterial hypertension: An update on current knowledge. Roldan T; Landzberg MJ; Deicicchi DJ; Atay JK; Waxman AB J Heart Lung Transplant; 2016 Feb; 35(2):151-64. PubMed ID: 26527532 [TBL] [Abstract][Full Text] [Related]
16. Pulmonary hypertension in thalassemia: association with platelet activation and hypercoagulable state. Singer ST; Kuypers FA; Styles L; Vichinsky EP; Foote D; Rosenfeld H Am J Hematol; 2006 Sep; 81(9):670-5. PubMed ID: 16795058 [TBL] [Abstract][Full Text] [Related]
17. [The current view on pathophysiology of pulmonary arterial hypertension]. Cisowska M; Lewczuk J Pol Merkur Lekarski; 2007 Apr; 22(130):286-90. PubMed ID: 17684928 [TBL] [Abstract][Full Text] [Related]
18. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. Quarck R; Nawrot T; Meyns B; Delcroix M J Am Coll Cardiol; 2009 Apr; 53(14):1211-8. PubMed ID: 19341863 [TBL] [Abstract][Full Text] [Related]
19. [Clinical classification and epidemiology of pulmonary arterial hypertension]. Chaouat A; Gomez E; Canuet M; Weitzenblum E; Chabot F Rev Prat; 2008 Nov; 58(18):1991-6. PubMed ID: 19143270 [TBL] [Abstract][Full Text] [Related]
20. The significance of diminished sTWEAK and P-selectin content in platelets of patients with pulmonary arterial hypertension. Kazimierczyk R; Błaszczak P; Kowal K; Jasiewicz M; Knapp M; Szpakowicz A; Ptaszyńska-Kopczyńska K; Sobkowicz B; Waszkiewicz E; Grzywna R; Musial WJ; Kamiński KA Cytokine; 2018 Jul; 107():52-58. PubMed ID: 29203267 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]